Diabetes. Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Intervention 1: All volunteers were examined by a general physician to assure that the intervention would not endanger patients. All participants gave their written informed consent. Group assignment:
Treatment - Other
All volunteers were examined by a general physician to assure that the intervention would not endanger patients. All participants gave their written informed consent. Group assignment: patients were d
control group received no intervention
Each phase in the RE group had three sessions per week which consisted of three phases of warm-up, the main, and cooling-down. The warm-up involved 20 minutes of stretching exercises and jogging on th
The group with CEs had the same schedule of other groups for warm-up and cooling-down. The main phase consisted of aerobic training integrated with RE, with half the execution time and the same intens
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
40 Years to 50 Years
Inclusion criteria
Inclusion criteria: The inclusion criteria were: having been suffering from T2DM (fasting blood sugar =126 mg/dl and 2-hour postprandial blood glucose =200 mg/dl) for at least 2 years; being female; aged 45 to 60 years exclusion criteria: diagnosed with any other diseases
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Insulin Resistance. Timepoint: At 2 stage. First day of the study (before any intervention) and second mesure after 12 weeks intervention. Method of measurement: ?????? ???? ?? ?????? ?? ??? ??????? ? ????? ?????: Insulin resistance =[fasting glucose (mg/dL)×fasting insulin (mU/L)/405]. | — |
Secondary
| Measure | Time frame |
|---|---|
| Before intervention, 5 mL blood samples were taken after 12 hours of fasting and the serum samples were separated using a centrifuge. The samples were frozen at –70° degrees centigrade until the time of serum analysis and omentin-1 and plasma glucose were then measured. Serum omentin-1 and fasting insulin concentrations were determined using enzyme-linked immunosorbent assay kits (Cristal day biotech, Shanghai, China) and (Monobind, Aachen, Germany). Fasting plasma glucose was measured using glucose kit (Pars Azmoon, Tehran, Iran) through the photometric method. Insulin resistance was determined through homeostasis model evaluation (HOMA-IR) and based on the following equation: HOMA-IR=[fasting glucose (mg/dL)×fasting insulin (mU/L)/405]. Timepoint: before intervention, 5 mL blood samples were taken after 12 hours of fasting and the serum samples were separated using a centrifuge. The samples were frozen at –70° degrees centigrade until the time of serum analysis and omentin-1 and plasma glucose were then measured. Serum omentin-1 and fasting insulin concentrations were determined using enzyme-linked immunosorbent assay kits (Cristal day biotech, Shanghai, China) and (Monobind, Aachen, Germany). Fasting plasma glucose was measured using glucose kit (Pars Azmoon, Tehran, Iran) through the photometric method. Insulin resistance was determined through homeostasis model evaluation (HOMA-IR) and based on the following equation: HOMA-IR=[fasting glucose (mg/dL)×fasting insulin (mU/L)/405]. Method of measurement: before intervention, 5 mL blood samples were taken after 12 hours of fasting and the serum samples were separated using a centrifuge. The samples were frozen at –70° degrees centigrade until the time of serum analysis and omentin-1 and plasma glucose were then measured. Serum omentin-1 and fasting insulin concentrations were determined using enzyme-linked immunosorbent assay kits (Cristal day biotech, Shanghai, China) and (Monobind, Aachen, Germany). Fasting plasm | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMostafa Dianati
Shiraz University of Medical Sciences
Outcome results
None listed